spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

SCORR Marketing and Applied Clinical Trials Release Report on Collaborative R&D in the Drug Development Industry

Applied Clinical Trials

Study on collaboration in the life sciences industry

Industry Kearney, Neb., Oct. 18, 2017

SCORR Marketing, a global health science marketing and communications firm, and Applied Clinical Trials have released a new study, Collaborative R&D Survey Report. The report details the extent to which collaboration in the life sciences industry occurs and provides insight into the factors that influence this collaboration.

“To fight the growing complexity and costs of drug development, drug sponsors are turning to a variety of strategies, one of which is collaborating on research and development (R&D),” said Anne-Marie Hess, senior strategic advisor at SCORR. “To help the industry better understand this strategy, we gathered information about attitudes toward collaborative R&D, its benefits and risks, which groups participate in such collaborations and why some partnerships are more productive than others.”

In addition, this report has information on why those in the industry think these arrangements are increasing, which stakeholders are more receptive to R&D partnerships and what types of medicines, therapeutic areas and medical devices will see more research and development through collaboration in the years ahead.

“Shared expertise and more efficient resource allocation were the two greatest perceived benefits of collaborative R&D,” said Lisa Henderson, group content director, Applied Clinical Trials, and Pharmaceutical Executive at UBM Americas. “What surprised us throughout the survey was the large discrepancy we found in some areas based on the respondents’ demographics — where their company was headquartered, the size of their company and their particular field.”

About SCORR Marketing
SCORR Marketing is the leading marketing and communications firm in the health sciences industry. We partner with organizations involved in global research, development and commercialization of biopharmaceutical and device products and the delivery of health care products and services. At SCORR, we achieve results for our clients by applying our proven, disciplined approach to synthesize market intelligence, strategy and creativity. We have locations across North America and Europe. For more information, visit www.scorrmarketing.com.
email lisa.henderson@ubm.com
email 485 Route 1 South Building F, Suite 210 Iselin, NJ 08830
 
Print this page
Send to a friend
   
spacer
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>


White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement